-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOCARE ANNOUNCES PHASE II STUDY RESULTS OF TYK2 INHIBITOR SOFICITINIB MEET PRIMARY ENDPOINT IN PATIENTS WITH VITILIGO

Reuters·07/16/2026 13:00:02

Please log in to view news